Answers are grounded in this paper and cite their sources.
Continuous monitoring using cardiovascular implantable electronic devices (CIEDs) allows for accurate assessment of atrial fibrillation (AF) duration and burden. Recent trials show that oral anticoagulant (OAC) reduces stroke risk in device-detected AF, though the AF duration threshold that benefits most from OAC has not been well established.
No takes yet. Share an insight, caveat, or question.
Passman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: